Autolus Therapeutics (NASDAQ:AUTL) Stock Price Up 10% - What's Next?

Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) shot up 10% during mid-day trading on Monday . The company traded as high as $1.92 and last traded at $1.93. 1,043,197 shares were traded during trading, a decline of 31% from the average session volume of 1,506,166 shares. The stock had previously closed at $1.75.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. Needham & Company LLC reiterated a "buy" rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a report on Thursday, April 10th. Truist Financial lowered their price target on Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Finally, Wells Fargo & Company decreased their target price on shares of Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating on the stock in a research report on Friday, March 21st. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $9.32.

Autolus Therapeutics Trading Up 1.0%

The company has a market capitalization of $556.23 million, a PE ratio of -1.73 and a beta of 1.77. The business has a fifty day moving average of $1.43 and a 200 day moving average of $1.99.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.02). The firm had revenue of $8.98 million for the quarter, compared to analyst estimates of $1.59 million. Equities analysts forecast that Autolus Therapeutics plc will post -0.94 EPS for the current fiscal year.

Hedge Funds Weigh In On Autolus Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Virtus ETF Advisers LLC increased its position in shares of Autolus Therapeutics by 29.9% during the fourth quarter. Virtus ETF Advisers LLC now owns 26,429 shares of the company's stock worth $62,000 after acquiring an additional 6,081 shares during the period. Daiwa Securities Group Inc. grew its stake in Autolus Therapeutics by 55.5% during the 4th quarter. Daiwa Securities Group Inc. now owns 23,743 shares of the company's stock worth $56,000 after purchasing an additional 8,479 shares in the last quarter. Barclays PLC increased its holdings in Autolus Therapeutics by 1,094.3% during the 4th quarter. Barclays PLC now owns 11,859 shares of the company's stock worth $28,000 after purchasing an additional 10,866 shares during the period. Jane Street Group LLC acquired a new stake in Autolus Therapeutics in the 4th quarter valued at about $26,000. Finally, Invesco Ltd. boosted its stake in shares of Autolus Therapeutics by 53.3% in the 1st quarter. Invesco Ltd. now owns 32,738 shares of the company's stock valued at $51,000 after buying an additional 11,381 shares during the period. Hedge funds and other institutional investors own 72.83% of the company's stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.